TY - JOUR
T1 - METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration
T2 - An initiative of the Joint Programme for Neurodegenerative Disease Research
AU - Dichgans, Martin
AU - Wardlaw, Joanna
AU - Smith, Eric
AU - Zietemann, Vera
AU - Seshadri, Sudha
AU - Sachdev, Perminder
AU - Biessels, Geert Jan
AU - Fazekas, Franz
AU - Benavente, Oscar
AU - Pantoni, Leonardo
AU - De Leeuw, Frank Erik
AU - Norrving, Bo
AU - Matthews, Paul
AU - Chen, Christopher
AU - Mok, Vincent
AU - Düring, Marco
AU - Whiteley, Will
AU - Shuler, Kirsten
AU - Alonso, Alvaro
AU - Black, Sandra E.
AU - Brayne, Carol
AU - Chabriat, Hugues
AU - Cordonnier, Charlotte
AU - Doubal, Fergus
AU - Duzel, Emrah
AU - Ewers, Michael
AU - Frayne, Richard
AU - Hachinski, Vladimir
AU - Ikram, Mohammad Arfan
AU - Jessen, Frank
AU - Jouvent, Eric
AU - Linn, Jennifer
AU - O'Brien, John
AU - van Oostenbrugge, Robert
AU - Malik, Rainer
AU - Mazoyer, Bernard
AU - Schmidt, Reinhold
AU - Sposato, Luciano A.
AU - Stephan, Blossom
AU - Swartz, Richard H.
AU - Vernooij, Meike
AU - Viswanathan, Anand
AU - Werring, David
AU - Abe, Koji
AU - Allan, Louise
AU - Arba, Francesco
AU - Diener, H. C.
AU - Davis, S.
AU - Hankey, G.
AU - Lees, K. R.
AU - Ovbiagele, B.
AU - Weir, C.
AU - Bae, Hee Joon
AU - Bath, Philip MW
AU - Bordet, Regis
AU - Breteler, Monique
AU - Choi, Seong
AU - Deary, Ian
AU - DeCarli, Charles
AU - Ebmeier, Klaus
AU - Feng, Lei
AU - Greenberg, Steven M.
AU - Ihara, Masafumi
AU - Kalaria, Rajesh
AU - Kim, San Yun
AU - Lim, Jae Sung
AU - Lindley, Richard I.
AU - Mead, Gillian
AU - Murray, Alison
AU - Quinn, Terry
AU - Ritchie, Craig
AU - Sacco, Ralph
AU - Al-Shahi Salman, Rustam
AU - Sprigg, Nikola
AU - Sudlow, Cathie
AU - Thomas, Alan
AU - van Boxtel, Martin
AU - van der Grond, Jeroen
AU - van der Lugt, Aad
AU - Yang, Yuan Han
N1 - Funding Information:
The following funders supported the work: Joint Programme for Neurodegenerative Disease (JPND) Research, specifically the UK Medical Research Council , the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), and the Canadian Institutes of Health Research (CIHR). The Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) through the Pools Engagement in Europe (PEER) funding from the Scottish Funding Council . The Therese Pei Fong Chow Research Centre for Prevention of Dementia (in memory of Donald H K Chow). The authors thank the Siemens Foundation, Munich, Germany, for providing the workshop venue and catering. F.-E.D.L. acknowledges VIDI Innovation Grant from ZonMW ref 016.126.351. P.M.M. acknowledges generous support from the Edmond J Safra Foundation and Lily Safra and the Imperial College Health Trust BRC. P.M.W.B. is Stroke Association Professor of Stroke Medicine. C.de.C. acknowledges support from Centre Grant NIH P30 AG 010129 . MD, JMW, GJB, RVO acknowledge EU Horizon 2020 SVDs@Target grant agreement No 666881.
Funding Information:
Declaration of interests: A Alonso, R Al-Shahi Salman, F Arba, H-J Bae, C Brayne, H Chabriat, C Chen, C Cordonnier, C DeCarli, M Dichgans, M Duering, F Fazekas, L Feng, S Greenberg, M Ihara, E Jouvent, R Kalaria, S-Y Kim, J-S Lim, RI Lindley, J Linn, R Malik, B Mazoyer, V Mok, B Norrving, L Pantoni, C Ritchie, R Sacco, R Schmidt, S Seshadri, L Sposato, N Sprigg, B Stephan, R Swartz, M van Boxtel, J Van der Grond, R van Oostenbrugge, M Vernooij, D Werring, W Whiteley, and V Zietemann have no disclosures. P Bath reports grants from UK Medical Research Council, NIHR Health Technology Assessment, Stroke Association, Alzheimer's Society, British Heart Foundation, during the conduct of the study. Outside the submitted work, S Black reports institutional grants from Pfizer, GE Healthcare, Eli Lilly, Elan/Transition Therapeutics, Roche, Cognoptix, and personal fees from Pfizer, GE Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, Novartis. R Bordet reports grants from French Minister of Health, Fondation Coeur et Artère, during the conduct of the study. I Deary reports grants from Age UK, UK Medical Research Council, UK Biotechnology and Biological Sciences Research Council, during the conduct of the study. F-E de Leeuw reports grants from VIDI innovational grant (ZonMW), during the conduct of the study. F Doubal reports grants from JPND (Medical Research Council and Canadian Institutes of Health Research), The Stroke Association and Garfield Weston Foundation, during the conduct of the study. KP Ebmeier reports grants from UK Medical Research Council, The HDH Wills 1965 Charitable Trust, Gordon Edward Small's Charitable Trust, National Institute of Health Research, Alzheimer Research UK, and personal fees from Eli Lily, GE, and grants from Various Pharmaceutical Companies, outside the submitted work. M Ewers received grants from the European Commission, Alzheimer Forschung Initiative and LMU. R Frayne reports grants from CIHR, during the conduct of the study; grants from CIHR, outside the submitted work. J O'Brien reports personal fees from GE Healthcare, TauRx, Cytox, grants and personal fees from Avid/Lilly, outside the submitted work. T Quinn is a founding member of VISTA cognition, a not for profit resource that collates individual patient level data relating to cognition and stroke. P Sachdev reports grants from NHMRC Program Grant ID 568969, during the conduct of the study. K Shuler reports grants from JPND (Medical Research Council), grants from Scottish Funding Council PEER SINAPSE, during the conduct of the study. E Smith reports grants from Canadian Institutes of Health Research, during the conduct of the study and from the Heart and Stroke Foundation of Canada, outside the submitted work. A Thomas reports grants from NIHR BRU in Lewy Body Dementia, during the conduct of the study. A Viswanathan reports personal fees from Roche Pharmaceuticals, outside the submitted work. JM Wardlaw reports grants from JPND (Medical Research Council and Canadian Institutes of Health Research), and Scottish Funding Council PEER SINAPSE, during the conduct of the study.
Publisher Copyright:
© 2016 The Authors
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Dementia is a global problem and major target for health care providers. Although up to 45% of cases are primarily or partly due to cerebrovascular disease, little is known of these mechanisms or treatments because most dementia research still focuses on pure Alzheimer's disease. An improved understanding of the vascular contributions to neurodegeneration and dementia, particularly by small vessel disease, is hampered by imprecise data, including the incidence and prevalence of symptomatic and clinically “silent” cerebrovascular disease, long-term outcomes (cognitive, stroke, or functional), and risk factors. New large collaborative studies with long follow-up are expensive and time consuming, yet substantial data to advance the field are available. In an initiative funded by the Joint Programme for Neurodegenerative Disease Research, 55 international experts surveyed and assessed available data, starting with European cohorts, to promote data sharing to advance understanding of how vascular disease affects brain structure and function, optimize methods for cerebrovascular disease in neurodegeneration research, and focus future research on gaps in knowledge. Here, we summarize the results and recommendations from this initiative. We identified data from over 90 studies, including over 660,000 participants, many being additional to neurodegeneration data initiatives. The enthusiastic response means that cohorts from North America, Australasia, and the Asia Pacific Region are included, creating a truly global, collaborative, data sharing platform, linked to major national dementia initiatives. Furthermore, the revised World Health Organization International Classification of Diseases version 11 should facilitate recognition of vascular-related brain damage by creating one category for all cerebrovascular disease presentations and thus accelerate identification of targets for dementia prevention.
AB - Dementia is a global problem and major target for health care providers. Although up to 45% of cases are primarily or partly due to cerebrovascular disease, little is known of these mechanisms or treatments because most dementia research still focuses on pure Alzheimer's disease. An improved understanding of the vascular contributions to neurodegeneration and dementia, particularly by small vessel disease, is hampered by imprecise data, including the incidence and prevalence of symptomatic and clinically “silent” cerebrovascular disease, long-term outcomes (cognitive, stroke, or functional), and risk factors. New large collaborative studies with long follow-up are expensive and time consuming, yet substantial data to advance the field are available. In an initiative funded by the Joint Programme for Neurodegenerative Disease Research, 55 international experts surveyed and assessed available data, starting with European cohorts, to promote data sharing to advance understanding of how vascular disease affects brain structure and function, optimize methods for cerebrovascular disease in neurodegeneration research, and focus future research on gaps in knowledge. Here, we summarize the results and recommendations from this initiative. We identified data from over 90 studies, including over 660,000 participants, many being additional to neurodegeneration data initiatives. The enthusiastic response means that cohorts from North America, Australasia, and the Asia Pacific Region are included, creating a truly global, collaborative, data sharing platform, linked to major national dementia initiatives. Furthermore, the revised World Health Organization International Classification of Diseases version 11 should facilitate recognition of vascular-related brain damage by creating one category for all cerebrovascular disease presentations and thus accelerate identification of targets for dementia prevention.
KW - Cerebrovascular disease
KW - Dementia
KW - Neurodegeneration, Cohorts, Survey
KW - Small vessel disease
UR - http://www.scopus.com/inward/record.url?scp=84995387428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995387428&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2016.06.004
DO - 10.1016/j.jalz.2016.06.004
M3 - Short survey
C2 - 27490018
AN - SCOPUS:84995387428
SN - 1552-5260
VL - 12
SP - 1235
EP - 1249
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 12
ER -